Evidence map›Paper›PMID 30006764›Full record

ArticleLa Radiologia medica2018

GUROPA survey: genito-urinary radiation oncology prescription attitudes.

Sergio Fersino, Stefano Arcangeli, Barbara Alicja Jereczek-Fossa, Rolando D'Angelillo, Filippi Bertoni, Giuseppe Roberto D'Agostino, Luca Triggiani, Renzo Corvò, Stefano Maria Magrini, Filippo Alongi and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in La Radiologia medica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Sergio FersinoRadiation Oncology Department, Ospedale Sacro-Cuore Don Calabria, Via Don A. Sempreboni 5, 37024, Negrar, Verona, Italy.
Stefano ArcangeliRadiation Oncology Department, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy.
Barbara Alicja Jereczek-FossaEuropean Institute of Oncology, University of Milan, Milan, Italy.
Rolando D'AngelilloDepartment of Radiation Oncology, Campus Biomedico University, Rome, Italy.
Filippi BertoniGenito-Urinary Group of AIRO - Italian Association for Radiation Oncology, Rome, Italy.
Giuseppe Roberto D'AgostinoRadiosurgery and Radiotherapy Department, Istituto Clinico Humanitas Cancer Center and Research Hospital, Rozzano, Milan, Italy.
Luca TriggianiDepartment of Radiation Oncology, University and Spedali Civili Hospital, Brescia, Italy.
Renzo CorvòDepartment of Radiation Oncology, IRCCS San Martino-IST National Cancer Research Institute and University, Genoa, Italy.
Stefano Maria MagriniDepartment of Radiation Oncology, University and Spedali Civili Hospital, Brescia, Italy.
Filippo AlongiRadiation Oncology Department, Ospedale Sacro-Cuore Don Calabria, Via Don A. Sempreboni 5, 37024, Negrar, Verona, Italy. prof.filippoalongi@gmail.com.
on the behalf of AIRO
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITOspedale Sacro Cuore Don Calabria · ITUniversità Campus Bio-Medico · ITAzienda Ospedaliera San Camillo-Forlanini · ITItalian Association for Cancer Research · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo investigate the role of Radiation Oncology in the management of genito-urinary (GU) cancer excluding prostate and penile cancer.

methodsThe questionnaire was focused on the evaluation of the degree of involvement of radiation oncologists in the work-up of bladder, renal cell carcinoma and testicular cancer (TC).

resultsEighty-eight radiation oncologists completed the survey. The majority (85.4%) of participating radiation oncologists were senior consultants (> 5 years of experience). Sixty-four (73.6%) carried out a multidisciplinary tumor board discussion of GU cases, while 23 (26.4%) did not. Seventy-five percent of responders reported that, every year, visited < 50 GU patients (pts), 18.1% visited 50-100 pts and 6.9% visited > 100 pts. Bladder cancer, curative radiotherapy (RT) as part of trimodality approach was claimed to be adopted in less than 10 cases per year. Regarding renal cell carcinoma (RCC) patients, primary tumor directed RT was adopted only in 8 cases (9.4%) in at least 10 pts per year. Palliative RT was more frequent in RCC (48.2%) in over than 10 pts per year. In case of TC, the prescription of RT was limited (< 10 patients per year) due to the low incidence of disease and recent shift to surveillance as a first option in stage I seminoma.

conclusionsOur survey showed that radiation oncologists are rarely involved in the decision making strategy of GU cancer, despite many clinical trials support RT use. These patients probably deserve a more uniform approach based on updated, detailed and evidence-based recommendations.

Indexed as

Radiation OncologyCarcinoma, Renal CellFemaleHumansItalyKidney NeoplasmsMalePractice Patterns, Physicians'Surveys and QuestionnairesTesticular NeoplasmsUrinary Bladder NeoplasmsCancerGenito-urinaryItalian surveyRadiotherapy

Identifiers

PMID30006764
OpenAlexW2883427353

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.